BioSpace News Archive

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a leading in vitro diagnostics company, today announced financial results for the second quarter ended July 3, 2022.

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2022 financial results and recent portfolio updates.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2022 financial results for the period ended June 30, 2022.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, August 11, 2022 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30,2022.

Acadia Pharmaceuticals Inc. announced that the Company has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its supplemental New Drug Application for NUPLAZID® for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

Geron Corporation announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations.

Maxar Technologies (NYSE:MAXR) (TSX:MAXR), provider of comprehensive space solutions and secure, precise, geospatial intelligence, announced it received a Phase A study contract from NASA for the National Oceanic and Atmospheric Administration’s (NOAA) Geostationary Extended Observations (GeoXO) Spacecraft mission.

RVL Pharmaceuticals plc, a specialty pharmaceutical company focused on the commercialization of UPNEEQ®, 0.1%, announced that it has entered into arrangements to secure up to $68.9 million in committed financing through a combination of equity and non-dilutive committed debt financing.